Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50–80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS: This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA1c <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant. RESULTS: The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA1c level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Islet cell transplantation, which has been shown to reduce hypoglycemia (48) and restore glucose counter-regulation (49), should be considered for people with type 1 diabetes who experience recurrent severe hypoglycemia (50)”
From Hypoglycemia (2018) · cites this paper as [48]
In the citing paper
“For people with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, pancreas transplant alone or human islet transplantation may be an option, but these approaches remain experimental (127,128).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [127]
In the citing paper
“Controlled trials 62,63 and followup of recipients 64,65 in major centres showed that high rates of insulin independence can be reached, and long duration of graft function is also seen; however,”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“Nevertheless, islet transplantation continues to be offered, with good outcomes, in many centres because of its effectiveness for treating hypoglycaemia and its usefulness in conjunction with kidney transplantation in people unsuitable for SPK.62”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“In addition, regulatory hurdles from the US FDA, despite pivotal trials done by the Collaborative Islet Transplant group, 62 have been a major stumbling block for the development of islet transplantation technology in the USA.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Self-citationStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942 · cited 2×
“5,000 islet equivalents (IEQ)/kg for the first dose and $4,000 IEQ/kg for subsequent doses (if any), was prepared from a single pancreas (14) and was transplanted by portal vein infusion.”
MethodResultSelf-citationStandards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,409
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Severe hypoglycemia is a debilitating, life-threatening complication of T1D (1,2,6,29) that, in some patients, is refractory to medical treatment (7,8,10).”
BackgroundStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651 · cited 1×
“Recipient Selection Inclusion criteria included the following: age 18–65 years; T1D for $5 years; absent stimulated C-peptide; IAH and/ or marked glycemic lability (19,20); and a history of SHEs in the prior 12 months despite medical care provided by an endocrinologist or diabetologist, who asserted that the candidate…”
BackgroundSelf-citation
Research works printed but not linked: 1
- Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1
Cited by
Items 101–200 of 705
Hope vs hype: where are we in type 1 diabetes?
Skyler, J. S. (2018) · Diabetologia · doi:10.1007/s00125-017-4530-x · Cited by 51
“Nonetheless, there has been a progressive improvement in outcomes [18], and the Clinical Islet Transplantation Consortium has completed a Phase III trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycaemia [19].”
BackgroundHering, B. J., Ballou, C. M., Bellin, M. D., Payne, E. H., Kandeel, F., Witkowski, P., Alejandro, R., Rickels, M. R., & Barton, F. B. (2023) · Diabetologia · doi:10.1007/s00125-022-05804-4 · Cited by 51
Self-citationA critical review and analysis of ethical issues associated with the artificial pancreas
Quintal, A., Messier, V., RABASA-LHORET, R. P. R., & Racine, É. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.04.003 · Cited by 51
Considerations and challenges of islet transplantation and future therapies on the horizon
Walker, S. L. M., Appari, M., & Forbes, S. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00310.2021 · Cited by 51
Moshref, M., Tangey, B., Gilor, C., Papas, K. K., Williamson, P., Loomba‐Albrecht, L. A., Sheehy, P. A., & Kol, A. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0163 · Cited by 50
β Cell Replacement Therapy: The Next 10 Years
Schuetz, C., Anazawa, T., Cross, S. E., Labriola, L., Meier, R. P. H., Redfield, R. R., Scholz, H., Stock, P. G., & Zammit, N. W. (2017) · Transplantation · doi:10.1097/tp.0000000000001937 · Cited by 49
Self-citationRegulated Cell Death Seen through the Lens of Islet Transplantation
Bruni, A. D. C., Bornstein, S. R., Linkermann, A., & Shapiro, A. M. J. (2018) · Cell Transplantation · doi:10.1177/0963689718766323 · Cited by 48
Self-citationvon Zur‐Mühlen, B., Lundgren, T., Bayman, L., Berne, C., Bridges, N. D., Eggerman, T. L., Foss, A. E., Goldstein, J., Jenssen, T. G., Jorns, C., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002425 · Cited by 48
“In this respect, the outcome of both treatment arms is comparable to that of the previously reported Protocol CIT-07.”
InfluentialSelf-citationStephens, C. H., Orr, K. S., Acton, A. J., Tersey, S. A., Mirmira, R. G., Considine, R. V., & Voytik‐Harbin, S. L. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2018 · Cited by 47
Encapsulated islet transplantation
Liu, S. S., Shim, S., Kudo, Y., Stabler, C. L., O’Cearbhaill, E. D., Karp, J. M., & Yang, K. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00238-6 · Cited by 46
“This regulatory barrier has created a pause in the availability of clinical islet transplantation in the USA after the completion of an National Institutes of Health (NIH)-sponsored multi-centre phase III trial (NCT00434811) 206 .”
Correction: Advances in islet encapsulation technologies
Desai, T. A., & Shea, L. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.67 · Cited by 46
Li, Y., Frei, A. W., Yang, E. Y., Labrada, I. M., Sun, C., Rong, Y., Samojlik, M. M., Bayer, A. L., & Stabler, C. L. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120182 · Cited by 45
Hu, M., Hawthorne, W. J., Nicholson, L., Burns, H., Yi, Q., Liuwantara, D., Vera, E. J., Chew, Y. V., Williams, L. J., Yi, S., et al. (2020) · Diabetes · doi:10.2337/db19-0525 · Cited by 44
“Rapamycin has also been reported in some studies to be toxic to islets; however, the extent of this remains controversial, and rapamycin remains the main immunosuppressive for preventing clinical islet allograft rejection (36,37).”
ResultNon-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond
Murakami, T., Fujimoto, H., & Inagaki, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.714348 · Cited by 43
“Whereas exendin (9-39) is a GLP-1 antagonist, exendin-3 and exendin-4 are GLP-1R agonists.”
BackgroundMethodInfluentialImmune Protection of Stem Cell-Derived Islet Cell Therapy for Treating Diabetes
Tahbaz, M., & Yoshihara, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.716625 · Cited by 43
Batra, L., Shrestha, P., Zhao, H., Woodward, K. B., Togay, A., Tan, M., Grimany-Nuno, O., Malik, M. T., Coronel, M. M., García, A. J., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000055 · Cited by 41
The future of type 1 diabetes therapy
Ziegler, A.-G., Cengiz, E., & Kay, T. W. H. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01438-2 · Cited by 42
Welsch, C. A., Rust, W. L., & CSETE, M. E. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0156 · Cited by 42
Diabetic Ketoacidosis Management: Updates and Challenges for Specific Patient Population
El‐Remessy, A. B. (2022) · Endocrines · doi:10.3390/endocrines3040066 · Cited by 42
“Tacrolimus remains one of the maintenance immunosuppression for islet transplant recipients with close monitoring for glucose levels and insulin secretions in these patients [40].”
BackgroundCurrent status of porcine islet xenotransplantation
Coe, T. M., Markmann, J. F., & Rickert, C. G. (2020) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000794 · Cited by 42
Self-citationKrentz, N. A. J., Shea, L. D., Huising, M. O., & Shaw, J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00170-4 · Cited by 42
A Worldwide Survey of Activities and Practices in Clinical Islet of Langerhans Transplantation
Berney, T., Andrès, A., Bellin, M. D., de Koning, E. J. P., Johnson, P., Kay, T. W. H., Lundgren, T., Rickels, M. R., Scholz, H., Stock, P. G., et al. (2022) · Transplant International · doi:10.3389/ti.2022.10507 · Cited by 42
Self-citationNo Time to Die—How Islets Meet Their Demise in Transplantation
Kale, A., & Rogers, N. M. (2023) · Cells · doi:10.3390/cells12050796 · Cited by 42
“, tremors and sweating) due to a loss of sympathetic and adreno-medullary counterregulatory mechanisms, as well as a lack of α-cell responsiveness [5,6].”
BackgroundHo, B. X., Teo, A. K. K., & Ng, N. H. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1375177 · Cited by 41
Encapsulation and immune protection for type 1 diabetes cell therapy
Kioulaphides, S., & García, A. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115205 · Cited by 42
Tondin, A. R., & Lanzoni, G. (2025) · BioDrugs · doi:10.1007/s40259-025-00703-7 · Cited by 40
“FDA Food and Drug Administration therapeutic modality to be tested in a series of large multi-center clinical trials [5–7].”
Bowers, D. T., Olingy, C. E., Chhabra, P., Langman, L. W., Merrill, P. H., Linhart, R. S., Tanes, M. L., Lin, D., Brayman, K. L., & Botchwey, E. A. (2017) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.33862 · Cited by 39
Survival After Islet Transplantation in Subjects With Type 1 Diabetes: Twenty-Year Follow-Up
Lemos, J. R. N., Baidal, D. A., Ricordi, C., Fuenmayor, V., Alvarez, A., & Alejandro, R. (2021) · Diabetes Care · doi:10.2337/dc20-2458 · Cited by 35
Self-citationGyörgy, J., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Winkler, G., & Wittmann, I. (2017) · Diabetologia Hungarica · doi:10.24121/dh.2017.1 · Cited by 40
Maffi, P., Nano, R., Monti, P., Melzi, R., Sordi, V., Mercalli, A., Pellegrini, S., Ponzoni, M., Peccatori, J., Messina, C. G. M., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002416 · Cited by 39
Samojlik, M. M., & Stabler, C. L. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.039 · Cited by 38
Landstra, C. P., Andrès, A., Chetboun, M., Conte, C., Kelly, Y. M., Berney, T., de Koning, E. J. P., Piemonti, L., Stock, P. G., Pattou, F. N., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab386 · Cited by 38
Self-citationHypoglycaemia in type 1 diabetes mellitus: risks and practical prevention strategies
Kaur, J., & Seaquist, E. R. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00762-8 · Cited by 38
The Role of Vitamin D and Omega-3 PUFAs in Islet Transplantation
Infante, M., Ricordi, C., Padilla, N., Alvarez, A., Linetsky, E., Lanzoni, G., Mattina, A., Bertuzzi, F., Fabbri, A., Baidal, D. A., et al. (2019) · Nutrients · doi:10.3390/nu11122937 · Cited by 37
Self-citationPignatelli, C., Campo, F., Neroni, A., Piemonti, L., & Citro, A. (2022) · Transplant International · doi:10.3389/ti.2022.10555 · Cited by 37
“Vivo Expression of Galalpha-(1, 3)Gal on Porcine Islet Cells Is Age”
BackgroundLessons and gaps in the prediction and prevention of type 1 diabetes
Mameli, C., Triolo, T. M., Chiarelli, F., Rewers, M., Zuccotti, G., & Simmons, K. M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106792 · Cited by 37
“[ 135 – 137] Of note, at this time, only insulin preparations and amylin are approved for use by the US FDA to treat T1D.”
Current issues in allogeneic islet transplantation
Chang, C., Lawrence, M. C., & Naziruddin, B. (2017) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000448 · Cited by 37
The Optimization of the Prevascularization Procedures for Improving Subcutaneous Islet Engraftment
Uematsu, S. S., Inagaki, A., Nakamura, Y., Imura, T., Igarashi, Y., Fathi, I., Miyagi, S., Ohuchi, N., Satomi, S., & Goto, M. (2017) · Transplantation · doi:10.1097/tp.0000000000001970 · Cited by 37
Frei, A. W., Li, Y., Jiang, K., Buchwald, P., & Stabler, C. L. (2017) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2464 · Cited by 36
“Clinical islet transplantation is a promising curative therapy for T1D, whereby donor allogeneic islets are infused into an extrapancreatic site, such as the portal vein of the liver (Hering et al., 2016; Shapiro et al., 2006).”
BackgroundHeterogeneity of Human Pancreatic Islet Isolation Around Europe: Results of a Survey Study
Nano, R., Kerr-Conte, J. A., Scholz, H., Engelse, M. A., Karlsson, M., Saudek, F., Bosco, D., Antonioli, B., Bertuzzi, F., Johnson, P., et al. (2019) · Transplantation · doi:10.1097/tp.0000000000002777 · Cited by 36
Self-citationKuppan, P., Kelly, S. E., Polishevska, K., Hojanepesov, O., Seeberger, K. L., Korbutt, G. S., & Pepper, A. R. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15662 · Cited by 36
“Allogeneic experimental groups were (1) empty micelles (no Dex) + islets (n = 5), (2) Dex-micelles + islets (n = 5), (3) empty micelles + islets +CTLA-4-Ig (n = 10), (4) Dex- micelles + islets +CTLA-4-Ig (n = 10), and (5) contralateral + CTLA-4-Ig (n = 7) where left KC received islets and right KC received Dexmicelles.”
MethodPancreatic islet transplantation: toward definitive treatment for diabetes mellitus
Takaki, T., & Shimoda, M. (2020) · Global Health & Medicine · doi:10.35772/ghm.2020.01057 · Cited by 36
“This advancement led to a multicenter, phase 3, prospective, open-label, single-arm study being conducted at 8 centers in North America with publication of the results in 2016 (12).”
BackgroundMethodInfluentialFrom islet of Langerhans transplantation to the bioartificial pancreas
Berney, T., Wassmer, C., Lebreton, F., Bellofatto, K., Fonseca, L. M., Bignard, J., Hanna, R., Peloso, A., & Berishvili, E. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104139 · Cited by 35
Advanced hydrogels for treatment of diabetes
Reyes-Martínez, J. E., Ruiz‐Pacheco, J. A., Flores‐Valdez, M. A., Elsawy, M. A., Vallejo‐Cardona, A. A., & Díaz, L. (2019) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2880 · Cited by 36
“When acute glycemic disorders are developed, patients can undergo islet or whole pancreas transplantation with relatively good prognosis (Hering et al., 2016; Lebovitz, 2011).”
BackgroundWoodward, K. B., Zhao, H., Shrestha, P., Batra, L., Tan, M., Grimany-Nuno, O., Bandura-Morgan, L., Askenasy, N., Shirwan, H., & Yolcu, E. S. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15747 · Cited by 35
Latres, E., Greenbaum, C. J., Oyaski, M. L., Dayan, C. M., Colhoun, H. M., Lachin, J. M., Skyler, J. S., Rickels, M. R., Ahmed, S. T., Dutta, S., et al. (2024) · Diabetes · doi:10.2337/dbi23-0012 · Cited by 35
Self-citationCatarinella, D., Melzi, R., Mercalli, A., Magistretti, P., Tentori, S., Gremizzi, C., Paloschi, V., COBELLI, F. D., Esposto, G., Costa, S., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00341-3 · Cited by 35
Inducible Pluripotent Stem Cells as a Potential Cure for Diabetes
Verhoeff, K., Henschke, S. J., Marfil-Garza, B. A., Dadheech, N., & Shapiro, A. M. J. (2021) · Cells · doi:10.3390/cells10020278 · Cited by 34
Self-citationA Century-long Journey From the Discovery of Insulin to the Implantation of Stem Cell–derived Islets
Ramzy, A., Belmonte, P. J., Braam, M. J. S., Ida, S., Wilts, E. M., Levings, M. K., Rezania, A., & Kieffer, T. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac021 · Cited by 34
Islet Cell Transplantion: Update on Current Clinical Trials
Schuetz, C., & Markmann, J. F. (2016) · Current Transplantation Reports · doi:10.1007/s40472-016-0103-z · Cited by 34
Self-citationAdvances in drug discovery for human beta cell regeneration
Karaköse, E., Ackeifi, C. A., Wang, P., & Stewart, A. F. (2018) · Diabetologia · doi:10.1007/s00125-018-4639-6 · Cited by 34
Tregs and Mixed Chimerism as Approaches for Tolerance Induction in Islet Transplantation
Pathak, S., & Meyer, E. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612737 · Cited by 34
New Aspects of Diabetes Research and Therapeutic Development
Satin, L. S., Soleimanpour, S. A., & Walker, E. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000160 · Cited by 34
A predictive computational platform for optimizing the design of bioartificial pancreas devices
Ernst, A. U., Wang, L., Worland, S. C., Marfil‐Garza, B. A., Wang, X., Liu, W. H., Chiu, A., Kin, T., O’Gorman, D., Steinschneider, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33760-5 · Cited by 34
“(S24)) 45 .”
Self-citationBaidal, D. A., Ballou, C., Rickels, M. R., Berney, T., Pattou, F. N., Payne, E. H., Barton, F. B., Alejandro, R., & CITR Investigators (2023) · Diabetes Care · doi:10.2337/dc22-1155 · Cited by 34
Self-citationEffects of islet transplantation on microvascular and macrovascular complications in type 1 diabetes
Reid, L. J., Baxter, F., & Forbes, S. (2021) · Diabetic Medicine · doi:10.1111/dme.14570 · Cited by 34
Evans‐Molina, C., Dor, Y., Lernmark, Å., Mathieu, C., Millman, J. R., Mirmira, R. G., Pociot, F., REDONDO, M. J., Rich, S. S., Richardson, S. J., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06462-y · Cited by 35
Self-citationTransplant Site Influences the Immune Response After Islet Transplantation: Bone Marrow Versus Liver
Cantarelli, E., Citro, A., Pellegrini, S., Mercalli, A., Melzi, R., Dugnani, E., Jofra, T., Fousteri, G., Mondino, A., & Piemonti, L. (2016) · Transplantation · doi:10.1097/tp.0000000000001462 · Cited by 33
Type 1 diabetes: where are we in 2017?
Copenhaver, M. M., & Hoffman, R. P. (2017) · Translational Pediatrics · doi:10.21037/tp.2017.09.09 · Cited by 34
Pharmacological Targeting of Endoplasmic Reticulum Stress in Pancreatic Beta Cells
Bilekova, S., Sachs, S., & Lickert, H. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.011 · Cited by 33
Safety and function of a new pre-vascularized bioartificial pancreas in an allogeneic rat model
Magisson, J., Sassi, A., Xhema, D., Kobalyan, A., Gianello, P., Mourer, B., Tran, N., Burcez, C., Aoun, R. B., & Sigrist, S. (2020) · Journal of Tissue Engineering · doi:10.1177/2041731420924818 · Cited by 32
Pancreatic Organoids for Regenerative Medicine and Cancer Research
Casamitjana, J., Espinet, E., & Rovira, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.886153 · Cited by 32
A Novel Subcutaneous Site of Islet Transplantation Superior to the Liver
Yasunami, Y., Nakafusa, Y., Nitta, N., Nakamura, M., Goto, M., Ono, J., & Taniguchi, M. (2018) · Transplantation · doi:10.1097/tp.0000000000002162 · Cited by 32
“Currently, the outcome of islet transplantation has been improved, such that more than 50% of IDDM recipients are insulin-free 5 years later,(2,3) and the serious complication of severe hypoglycemic events is resolved after islet transplantation.(4,5) However, several important issues remain to be resolved, including…”
BackgroundVanderlaan, E. L., Nolan, J. K., Sexton, J., Evans‐Molina, C., Lee, H., & Voytik‐Harbin, S. L. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115409 · Cited by 31
Applications of Genome-Editing Technologies for Type 1 Diabetes
Nahas, R. E., Al‐Aghbar, M. A., Herrero, L., van Panhuys, N., & Espino‐Guarch, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010344 · Cited by 31
“Further, the use of transplanted purified human pancreatic islets in medically unstable T1D patients resulted in glycemic control, restoration of hypoglycemia awareness, and protection from severe hypoglycemia [45].”
Immunological Issues After Stem Cell-Based β Cell Replacement
Sordi, V., Pellegrini, S., & Piemonti, L. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0901-4 · Cited by 31
Citro, A., Cantarelli, E., Pellegrini, S., Dugnani, E., & Piemonti, L. (2017) · Transplantation · doi:10.1097/tp.0000000000001925 · Cited by 31
“Copyright © 2018 Wolters Kluwer improved metabolic control even when exogenous insulin is required (ie, suboptimal islet mass transplanted or development of graft dysfunction).(1,2) Although significant progress has beenmade in the islet transplantation field,(3,4) several limitations remain that currently preclude it…”
BackgroundTakaichi, S., Tomimaru, Y., Akagi, T., Kobayashi, S., Fukuda, Y., Toya, K., Asaoka, T., Iwagami, Y., Yamada, D., Akita, H., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003745 · Cited by 30
Campa‐Carranza, J. N., Paez‐Mayorga, J., Chua, C. Y. X., Nichols, J. E., & Grattoni, A. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2076834 · Cited by 30
“For pancreatic islet transplantation, current clinical protocols generally include systemic T cell depletion, a tumor necrosis factor α (TNF-α) blocker, tacrolimus, and sirolimus [48,49].”
BackgroundRen, G., Rezaee, M., Razavi, M., Taysir, A., Wang, J., & Thakor, A. S. (2019) · Cell and Tissue Research · doi:10.1007/s00441-019-02997-w · Cited by 30
A steady decline in pancreas transplantation rates
Benjamens, S., Leemkuil, M., Margreiter, C., Huurman, V. A. L., Leuvenink, H. G. D., & Pol, R. A. (2018) · Pancreatology · doi:10.1016/j.pan.2018.11.003 · Cited by 29
Alwahsh, S. M., Qutachi, O., Lewis, P. J. S., Bond, A., Noble, J., Burgoyne, P., Morton, N. M., Carter, R., Mann, J., Ferreira-González, S., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16488 · Cited by 29
Utilizing Xenogeneic Cells As a Therapeutic Agent for Treating Diseases
Huang, C., Yang, C., & Shyr, C. (2021) · Cell Transplantation · doi:10.1177/09636897211011995 · Cited by 29
Lemos, N. E., Brondani, L. D. A., Dieter, C., Rheinheimer, J., Bouças, A. P., Leitão, C. B., Crispim, D., & Bauer, A. C. (2017) · Islets · doi:10.1080/19382014.2017.1335842 · Cited by 28
Nishime, K., Miyagi‐Shiohira, C., Kuwae, K., Tamaki, Y., Yonaha, T., Sakai‐Yonaha, M., Saitoh, I., Watanabe, M., & Noguchi, H. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16401 · Cited by 28
Zeynaloo, E., Stone, L. D., Dikici, E., Ricordi, C., Deo, S. K., Bachas, L. G., Daunert, S., & Lanzoni, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101063 · Cited by 27
Self-citationmTOR Inhibition and Clinical Transplantation: Pancreas and Islet
Berney, T., Andrès, A., Toso, C., Majno, P. E., & Squifflet, J. (2017) · Transplantation · doi:10.1097/tp.0000000000001700 · Cited by 27
“7 SRL- or everolimus-based IS regimens have achieved prolonged graft function (positive Cpeptide), controlled HbA1c and disappearance of severe hypoglycemia in a majority of islet transplant recipients (9,10).”
Porcine Islet Xenografts: a Clinical Source of ß-Cell Grafts
Salama, B. F., & Korbutt, G. S. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0846-7 · Cited by 27
Peloso, A., Citro, A., Zoro, T., Cobianchi, L., Kahler‐Quesada, A., Bianchi, C. M., Andrès, A., Berishvili, E., Piemonti, L., Berney, T., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00445 · Cited by 28
“The results of islet transplantation, initially providing an insulin-independence rate lower than 20% after 1 year, noticeably improved with the introduction of the Edmonton protocol (8), achieving glycaemia stabilization in 88% of patients after 1 year and 71% after 2 years (9).”
MethodIslet Transplantation Alone Versus Solitary Pancreas Transplantation: an Outcome-Driven Choice?
Maffi, P., & Secchi, A. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1145-2 · Cited by 27
Nakamura, T., Fujikura, J., Anazawa, T., Ito, R., Ogura, M., Okajima, H., Üemoto, S., & Inagaki, N. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13128 · Cited by 27
Current situation of clinical islet transplantation from allogeneic toward xenogeneic
Matsumoto, S., & Shimoda, M. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13041 · Cited by 26
“1% of patients received three infusions.(3) It seems the standard of allogeneic islet transplantation is in the transition period from multiple infusion to single infusion.”
BackgroundMethodThe Influence of Microenvironment on Survival of Intraportal Transplanted Islets
Yan, L., Ye, L., Chen, Y., He, S.-Q., Zhang, C., Mao, X., & Li, S.-W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.849580 · Cited by 26
“6% in the absence of severe hypoglycemia (17).”
BackgroundThe Spleen Is an Ideal Site for Inducing Transplanted Islet Graft Expansion in Mice
Itoh, T., Nishinakamura, H., Kumano, K., Takahashi, H., & Kodama, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170899 · Cited by 26
Pellegrini, S., Manenti, F., Chimienti, R., Nano, R., Ottoboni, L., Ruffini, F., Martino, G., Ravassard, P., Piemonti, L., & Sordi, V. (2018) · Cell Transplantation · doi:10.1177/0963689718798564 · Cited by 26
Senior, P. A., & Pettus, J. (2018) · Diabetic Medicine · doi:10.1111/dme.13846 · Cited by 26
Self-citationKuppan, P., Seeberger, K. L., Kelly, S. E., Rosko, M., Adesida, A. B., Pepper, A. R., & Korbutt, G. S. (2020) · Xenotransplantation · doi:10.1111/xen.12581 · Cited by 26
3D Bioprinting and Translation of Beta Cell Replacement Therapies for Type 1 Diabetes
Gurlin, R. E., Giraldo, J. A., & Latres, E. (2020) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2020.0192 · Cited by 26
“Based on preclinical research 86,87 and clinical evidence of islet transplantation, 88 there is no need to recreate an entire pancreas and as such the goal is to create a construct that, once implanted, results in survival and function of the beta cell graft.”
Islet transplantation for hypoglycemia unawareness/severe hypoglycemia: caveat emptor
Harlan, D. M. (2016) · Diabetes Care · doi:10.2337/dci16-0008 · Cited by 25
Pertusa, J. A. G., León‐Quinto, T., Berná, G., Tejedo, J. R., Hmadcha, A., Bedoya, F. J., Martín, F., & Soria, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187547 · Cited by 25
Evans‐Molina, C., Dor, Y., Lernmark, Å., Mathieu, C., Millman, J. R., Mirmira, R. G., Pociot, F., REDONDO, M. J., Rich, S. S., Richardson, S. J., et al. (2025) · Diabetes Care · doi:10.2337/dci25-0013 · Cited by 24
Self-citationDadlani, V., Kaur, R. J., Stegall, M. D., Xyda, S., Kumari, K., Bonner, K., Smith, B. H., Thapa, P. B., Dean, P. G., & Kudva, Y. C. (2019) · Clinical Transplantation · doi:10.1111/ctr.13719 · Cited by 24
Brandhorst, D., Brandhorst, H., Layland, S. L., Acreman, S., Schenke‐Layland, K., & Johnson, P. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.10.013 · Cited by 24
Future Directions for Adrenal Insufficiency: Cellular Transplantation and Genetic Therapies
Graves, L. E., Torpy, D. J., Coates, P. T., Alexander, I. E., Bornstein, S. R., & Clarke, B. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac751 · Cited by 24
Verheyen, C. A., Morales, L. C., Sussman, J., Paunovska, K., Manzoli, V., Ziebarth, N., & Tomei, A. A. (2019) · Macromolecular Materials and Engineering · doi:10.1002/mame.201800679 · Cited by 24
The greater omentum as a site for pancreatic islet transplantation.
Pellicciaro, M., Vella, I., Lanzoni, G., Tisone, G., & Ricordi, C. (2017) · PubMed · Cited by 24
Self-citationForbes, S., Flatt, A. J., Bennett, D., Crookston, R. M., Pimkova, M., Birtles, L., Pernet, A., Wood, R., Burling, K., Barker, P. J., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16785 · Cited by 24
“Single infusion n=23 12 (11-12) month follow-up Assessed for eligibility UKITC dataset First transplant between 01/04/08 and 01/04/15 (inclusive) N=90 recipients”
Graham, M. L., Ramachandran, S., Singh, A. R., Moore, M. E. G., Flanagan, E. B., Azimzadeh, A. M., Burlak, C., Mueller, K. R., Martins, K. V., Anazawa, T., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16876 · Cited by 24
“In vitro and in vivo expression of Galalpha- (1,3)Gal on porcine islet cells is age dependent.”
BackgroundSelf-citationDeng, H., Zhang, A., Pang, D. R. R., Xi, Y., Yang, Z., Matheson, R., Li, G., Luo, H. L., Lee, K. M., Fu, Q., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100959 · Cited by 25
“Clinical trials also revealed that progressive graft dysfunction over time after intrahepatic islet transplantation and often requiring administration of exogenous insulin.(4,5,7) Importantly, the liver cannot accommodate encapsulated islets(8) or co-implantation of islets and immunomodulatory material for local immun…”
BackgroundSelf-citationWho Should Be Considered for Islet Transplantation Alone?
Othonos, N., & Choudhary, P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0847-6 · Cited by 24
Metadata
- Authors
- Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., Kaufman, D. B., Korsgren, O., Larsen, C. P., Luo, X., Markmann, J. F., Naji, A., Oberholzer, J., Posselt, A. M., Rickels, M. R., Ricordi, C., Robien, M. A., Senior, P. A., Shapiro, A. M. J., Stock, P. G., Turgeon, N. A., & for the Clinical Islet Transplantation Consortium
- Affiliations
- University of Minnesota (US)
- University of Iowa (US)
- National Institutes of Health (US)
- University of Miami (US)
- University of Wisconsin–Madison (US)
- Uppsala University (SE)
- Emory University (US)
- Northwestern University (US)
- Harvard University (US)
- University of Pennsylvania (US)
- Division of Transplantation, University of Illinois Hospital and Health Sciences System, Chicago, IL
- University of California, San Francisco (US)
- University of Alberta (CA)
- Corresponding author
- Clarke, William R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-04-18
- Volume
- 39
- Issue
- 7
- Pages
- 1230-1240
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC5317236
- OpenAlex
- W2341414956
- Cited by
- 645
- References
- 40
- Citations by year
- 2026: 25 · 2025: 51 · 2024: 47 · 2023: 67 · 2022: 75 · 2021: 88 · 2020: 60 · 2019: 79 · 2018: 73 · 2017: 60 · 2016: 20
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases
- National Institute for Diabetes and Digestive and Kidney Diseases (U01-AI-089317, 1-AI-089316, 1-AI-065191, U01-DK-085531, 5U01-DK-070431-10, U01-DK-070431, U01-DK-070460, U01-AI-065193, U01-DK-070430, U01-AI-065192)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, islet transplantation, severe hypoglycemia, hypoglycemia unawareness, glycemic control, HbA1c, immunosuppression, bleeding complications, glomerular filtration rate, donor-specific antibodies, renal function decline, islet autoimmunity
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Immunosuppression Therapy, Male, Middle Aged, North America, Islets of Langerhans Transplantation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.